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Background: The optimal dose of aspirin after primary PCI in STEMI is unknown. We therefore assessed the relationship between discharge aspirin 
dose and long-term outcomes in pts undergoing primary PCI from the large, randomized HORIZONS-AMI trial.
Methods: HORIZONS-AMI was a dual arm, factorial trial in pts with STEMI. After a loading dose, aspirin 300 - 325 mg/d was given in hospital, with 
at least 75 mg/d prescribed at discharge (dose per operator discretion) and continued indefinitely. Clopidogrel was required for ≥6 months (≥12 
months recommended). For the present analysis clinical outcomes were examined according to the aspirin discharge dose (low-dose; ≤100mg/d, vs. 
high-dose; >100mg/d).
Results: Among pts undergoing PCI, 2311 (76.3%) were discharged on low-dose aspirin, with 717 (23.7%) receiving high-dose. At 3 yr follow-
up, the rate of net adverse clinical events (MACE or major non-CABG related bleeding) favored the low-dose group (RR 0.68, 95%CI: 0.58 - 0.79) 
(Figure). MACE, major bleeding and TVR were also reduced in the low-dose group (Figure). However, by multivariate regression, aspirin dose was not 
an independent predicator of 3 year MACE.
Conclusions: After primary PCI, pts discharged on >100mg/d aspirin had higher 3-year rates of MACE and bleeding events, differences which may 
be attributed to baseline imbalances between the groups. An appropriately designed and powered randomized trial is required to determine the 
optimal aspirin dose after primary PCI in STEMI.
